Loading
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Latest quote
$1.68
+$0.01 · +0.60%
After-hours
$1.6699
−$0.0101 · -0.60%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Day range
Current $1.68
52-week range
Current $1.68
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
74
Undervalued
Sentiment
49
Mixed
Risk
67
High Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Day range
Current $1.68
52-week range
Current $1.68
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 56.65M USD | 51.29M USD | 39.3M USD | 22.47M USD | 13.04M USD |
| Cost of goods sold | 8.31M USD | 8.33M USD | 6.26M USD | 5M USD | 3.64M USD |
| Gross profit | 48.34M USD | 42.96M USD | 33.04M USD | 17.47M USD | 9.4M USD |
| Research and development | 11.13M USD | 11.13M USD | 11.63M USD | 9.95M USD | 7.5M USD |
| Selling, general, and administrative | 88.47M USD | 91.32M USD | 64.51M USD | 50.05M USD | 27.86M USD |
| Operating expenses | 99.61M USD | 102.45M USD | 76.14M USD | 60M USD | 35.36M USD |
| Interest expense | 5.83M USD | 4.4M USD | 1.8M USD | 165K USD | 2.22M USD |
| Depreciation and amortization | 756K USD | 619K USD | 522K USD | 412K USD | 168K USD |
| Operating income | −51.27M USD | −59.49M USD | −43.1M USD | −42.53M USD | −25.97M USD |
| Net income | −53.31M USD | −59.97M USD | −41.2M USD | −41.43M USD | −43.08M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.30
155.95% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.02M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM632.56K0.00%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF605.42K0.00%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO262.85K0.00%14.04B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO260.73K0.00%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC81.64K0.01%1.33B USD0.60%$182.79-0.31%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM60K0.05%116.75M USD0.73%$15.90-0.44%
Vanguard Russell 2000 Growth ETFVTWG51.58K0.00%1.7B USD0.06%$258.14-0.44%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
